PF-Atlas › Clinical Trials › NCT02990286

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases

Rituximab · Phase 3

Registry ID
NCT02990286
Phase
Phase 3
Status
Completed
Drug / intervention
Rituximab
Sponsor
University Hospital, Tours
Start
2017-01-20
Enrollment
122
Locations
5

About this trial

The purpose of the study is to evaluate the efficacy on lung function 6 months after one course of rituximab (2 infusions) and mycophénolate mofétil (MMF) treatment compared to one course of placebo and 6 months of MMF treatment in a broad range of patients with Interstitial Lung Diseases (ILD) non-responders to a first line immunosuppressive treatment.

View NCT02990286 on ClinicalTrials.gov →

Explore related

All Rituximab trialsAll IPF trials

Related trials

Rituximab — NCT01086540Rituximab — NCT01862926Rituximab — NCT05596786Rituximab — NCT03069248Rituximab — NCT01969409Rituximab — NCT01748084
Medical disclaimer. This page summarizes public trial data for NCT02990286 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.